Efalizumab Efficiency

San Francisco -- Results from Phase III clinical trials support the efficacy and safety of efalizumab (Raptiva), the humanized CD-11a monoclonal antibody, as a chronic treatment for moderate-to-severe plaque psoriasis, Kim A. Papp, M.D., said at the annual meeting of the American Academy of Dermatology.

Related Videos
Related Content

Iovance Completes Biologics License Application (BLA) Submission for Advanced Melanoma Drug

March 28th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

5 Perspectives on Laser Treatment in Dermatology

March 28th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Adel Haque, MD, Provides His Best Advice for New Dermatologists

March 28th 2023

Recent Povorcitinib 2b Study Shows Improved Repigmentation

March 27th 2023

Iovance Completes Biologics License Application (BLA) Submission for Advanced Melanoma Drug

March 28th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

5 Perspectives on Laser Treatment in Dermatology

March 28th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Adel Haque, MD, Provides His Best Advice for New Dermatologists

March 28th 2023

Recent Povorcitinib 2b Study Shows Improved Repigmentation

March 27th 2023

Iovance Completes Biologics License Application (BLA) Submission for Advanced Melanoma Drug

March 28th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

5 Perspectives on Laser Treatment in Dermatology

March 28th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Adel Haque, MD, Provides His Best Advice for New Dermatologists

March 28th 2023

Recent Povorcitinib 2b Study Shows Improved Repigmentation

March 27th 2023
© 2023 MJH Life Sciences

All rights reserved.